Abstract
Get full access to this article
View all access options for this article.
References
1.
Philippidis
A.
PASTE, Don't Cut: Genome Editing Tool Looks Beyond CRISPR and Prime. Genetic Engineering & Biotechnology News; March 10, 2023. Available from: https://www.genengnews.com/topics/genome-editing/paste-dont-cut-genome-editing-tool-looks-beyond-crispr-and-prime/ [Last accessed: March 15, 2023].
2.AbbVie and Capsida Biotherapeutics . AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need; February 23, 2023. Available from: https://news.abbvie.com/news/press-releases/abbvie-and-capsida-biotherapeutics-expand-strategic-collaboration-to-develop-targeted-genetic-medicines-for-eye-diseases-with-high-unmet-need.htm [Last accessed: March 15, 2023].
3.Aera Therapeutics . Aera Therapeutics Launches with $193 Million in Financing to Enable and Advance the Next Generation of Transformative Genetic Medicines; February 16, 2023. Available from: https://aeratx.com/aera-therapeutics-launches-with-193-million-in-financing-to-enable-and-advance-the-next-generation-of-transformative-genetic-medicines/ [Last accessed: March 15, 2023].
4.
LeMieux
J.
Feng Zhang's Delivery Platform Launched by Aera Therapeutics. Genetic Engineering & Biotechnology News; February 16, 2023. Available from: https://www.genengnews.com/topics/omics/gene-expression/gene-delivery/feng-zhangs-delivery-platform-launched-by-aera-therapeutics/ [Last accessed: March 15, 2023].
5.Orchard Therapeutics . Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million; March 6, 2023. Available from: https://ir.orchard-tx.com/news-releases/news-release-details/orchard-therapeutics-announces-strategic-financing-totalling-188 [Last accessed: March 15, 2023].
6.
Philippidis
A.
Up or Down: Chroma Medicine Raises Stakes in Epigenetic Editing. Genetic Engineering & Biotechnology News; March 11, 2023. Available from: https://www.genengnews.com/topics/genome-editing/up-or-down-chroma-medicine-raises-stakes-in-epigenetic-editing/ [Last accessed: March 15, 2023].
7.Chroma Medicine . Chroma Medicine Secures $135M in Series B Financing to Advance Breakthrough Epigenetic Editing Technology and Expand Pipeline of Durable Precision Genomic Medicines; March 1, 2023. Available from: https://chromamedicine.com/2023/03/01/chroma-medicine-secures-135m-in-series-b-financing-to-advance-breakthrough-epigenetic-editing-technology-and-expand-pipeline-of-durable-precision-genomic-medicines/ [Last accessed: March 15, 2023].
8.BioMarin Pharmaceutical . BioMarin Provides Update on FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) Gene Therapy for Adults with Severe Hemophilia A; March 6, 2023. Available from: https://investors.biomarin.com/2023-03-06-BioMarin-Provides-Update-on-FDA-Review-of-ROCTAVIAN-TM-Valoctocogene-Roxaparvovec-Gene-Therapy-for-Adults-with-Severe-Hemophilia-A [Last accessed: March 15, 2023].